CN114164150A - Method for inhibiting synthesis of staphylococcal flavin and application thereof - Google Patents
Method for inhibiting synthesis of staphylococcal flavin and application thereof Download PDFInfo
- Publication number
- CN114164150A CN114164150A CN202111442761.9A CN202111442761A CN114164150A CN 114164150 A CN114164150 A CN 114164150A CN 202111442761 A CN202111442761 A CN 202111442761A CN 114164150 A CN114164150 A CN 114164150A
- Authority
- CN
- China
- Prior art keywords
- eugenol
- flavin
- synthesis
- staphylococcal
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 27
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 23
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 15
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 82
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000005770 Eugenol Substances 0.000 claims abstract description 41
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960002217 eugenol Drugs 0.000 claims abstract description 41
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 27
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 13
- 241000894006 Bacteria Species 0.000 claims abstract description 12
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims abstract description 9
- 229960003085 meticillin Drugs 0.000 claims abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 11
- 150000002211 flavins Chemical class 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 238000003501 co-culture Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000012452 mother liquor Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 4
- 230000035899 viability Effects 0.000 abstract description 4
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 238000001069 Raman spectroscopy Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 244000045719 Syzygium Species 0.000 description 1
- 235000012096 Syzygium samarangense Nutrition 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- PDOUICUKTQRPHO-MENSNCDRSA-N staphyloxanthin Chemical group CCC(C)CCCCCCCCCCC(=O)OC[C@H]1O[C@@H](OC(=O)C(\C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C)[C@H](O)[C@@H](O)[C@@H]1O PDOUICUKTQRPHO-MENSNCDRSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for inhibiting staphylococcus aureus flavin synthesis and application thereof, relates to the field of microbial antibacterial agents, and provides a method for effectively relieving and solving the problems of staphylococcus aureus resistance development and pathogenesis under the condition that eugenol can inhibit the synthesis of methicillin-sensitive bacteria (MSSA) and methicillin-resistant staphylococcus aureus (MRSA) flavin without influencing the viability of staphylococcus aureus according to the fact that eugenol can inhibit the synthesis of methicillin-sensitive bacteria (MSSA) and the Minimum Inhibitory Concentration (MIC) of methicillin-resistant staphylococcus aureus (MRSA), and is obviously lower than the Minimum Inhibitory Concentration (MIC) (800-.
Description
Technical Field
The invention relates to the field of microbial antibacterial agents, and particularly relates to a eugenol antibacterial agent and application thereof.
Background
Since 1980, the number of global cases of food-borne diseases has been increasing, and prevention, control and treatment of food-borne diseases have become one of the problems to be overcome in the world public health field. The World Health Organization (WHO) global antibiotic monitoring results show that the antibiotic resistance phenomenon generally occurs in 50 suspected bacteria infected patients in 22 countries, and Chinese antibiotic resistance monitoring reports show that among gram-positive pathogenic bacteria, staphylococcus aureus (s. aureus) and methicillin-resistant staphylococcus aureus (MRSA) strains have the highest infection rate, wherein the rapid occurrence, spread and prevalence of multi-drug resistant staphylococcus aureus, particularly MRSA, cause most of antibiotics to fail, and the development difficulty of new antibiotics is extremely high, so that a long process is often needed, and the conditions of human diseases caused by infection of staphylococcus aureus are increased continuously.
Currently, the "indirect killing" strategy, which focuses on the use of the host immune system, can achieve a reduction in the pathogenic capacity of the bacteria without directly affecting their viability, thereby significantly slowing the development of drug resistance. The anti-virulence strategy is one of the "indirect" antibacterial means, which can intervene, regulate or destroy the virulence of the microorganisms without directly killing them, and provides a new choice for fighting pathogenic bacteria.
The Chinese herbal medicine is a unique natural medicine obtained by exploration and practice of human beings for thousands of years, and has the characteristics of wide resources, low cost, stable action, small toxic and side effects, difficult generation of drug resistance and capability of comprehensively regulating the functions of organisms, so that the effective components of the Chinese herbal medicine are an important resource library for developing antibiotics to replace medicines. Clove is a plant of the genus Syzygium of the family Myrtaceae, and phenols represented by eugenol are important active ingredients of clove, and researches show that eugenol has bacteriostatic and antiviral effects and can be used as a spice for soaps and administration, but the condition that eugenol can inhibit the synthesis of staphylococcal flavin under the condition that the survival capacity of staphylococcus aureus is not influenced is not reported.
In view of the above facts, those skilled in the art have focused on the discovery of active ingredients capable of inhibiting the synthesis of staphylococcal flavins beyond conventional antibiotic treatment strategies, and have developed antibacterial agents with novel mechanisms of action to address the treatment of S.aureus infections.
Disclosure of Invention
In order to achieve the purpose, the invention adopts the following technical scheme:
the first object of the present invention is to provide a method for inhibiting the synthesis of staphylococcal flavins, comprising the steps of:
step 1, dipping the frozen starting strain for amplification culture, resuspending the strain with physiological saline, adjusting the OD value of the bacterial liquid to 0.1, and then diluting the bacterial liquid with a TSB culture medium;
step 2, preparing a eugenol solution;
step 3, mixing the eugenol solution into the bacterial liquid obtained in the step 1 for co-culture;
and 4, detecting the OD value of the bacteria liquid after co-culture.
Preferably, the bacterial fluid is diluted 1000-fold using TSB medium.
Preferably, the physiological saline is 1mL of 0.85% physiological saline.
Preferably, step 2 comprises preparing 100mg/mL eugenol mother liquor by using dimethyl sulfoxide as a solvent, and diluting to different concentrations.
Preferably, the co-cultivation time is 24 h.
The second purpose of the invention is to provide a eugenol antibacterial agent prepared by a method for inhibiting the synthesis of staphylococcal flavin, which comprises dimethyl sulfoxide and eugenol, wherein the dimethyl sulfoxide is a solvent.
In one embodiment, the minimum inhibitory concentration MIC of eugenol is 800-1000 μ g/mL.
In one embodiment, the eugenol minimal inhibitory staphylococcal flavin concentration MSIC is 300 μ g/mL.
The third purpose of the invention is to provide the application of the eugenol antibacterial agent in inhibiting the synthesis of the staphylococcus aureus flavin.
Further, the staphylococcus aureus is methicillin-sensitive (MSSA), methicillin-resistant staphylococcus aureus (MRSA) standard strain and food source strain.
Has the advantages that:
the invention provides a method for inhibiting synthesis of staphylococcal flavin and application thereof. The method for inhibiting the synthesis of the staphylococcus aureus flavin by utilizing the Chinese herbal medicine effective component eugenol under the condition of not influencing the viability of the staphylococcus aureus is expected to relieve and solve the problems of drug resistance development and pathogenicity of the staphylococcus aureus by adopting an antitoxic strategy, provides a new idea for preventing and controlling the staphylococcus aureus, and has wide application potential in the fields of food, medicines and human health.
The conception and the resulting technical effects of the present invention will be further described with reference to the accompanying drawings to fully understand the objects, features and effects of the present invention.
Drawings
In the drawings of the present invention, fig. 1 and 2 are marked to represent: (A) s.aureus ATCC 43300(B) s.aureus SJTUF21656 (C) s.aureus ATCC 29213(D) s.aureus SJTUF 21660; fig. 3 symbols represent: (A) s.aureus ATCC 29213(B) s.aureus ATCC 43300(C) s.aureus newman (d) s.aureus CrtN knockout and anaplerosis;
FIG. 1 is a graph showing growth curves of different bacteria-producing solutions under the action of eugenol;
FIG. 2 shows the effect of eugenol on inhibiting flavins in different bacteria-producing solutions
FIG. 3 is a Raman spectrum image of the flavin extract under different treatment conditions.
Detailed Description
The technical contents of the preferred embodiments of the present invention will be more clearly and easily understood by referring to the drawings attached to the specification. The present invention may be embodied in many different forms of embodiments and the scope of the invention is not limited to the embodiments set forth herein.
Example 1: and (4) measuring the growth curve of the staphylococcus aureus under the action of the eugenol.
A series of eugenol treatment groups with concentration gradients are set by taking MRSA standard strain ATCC 43300, food source strain SJTUF21656, MSSA standard strain ATCC 29213 and food source strain SJTUF 21660 as starting strains to study the influence of the strains on the viability of staphylococcus aureus.
Firstly, the bacterial liquid frozen at-80 ℃ is dipped, streaked and inoculated to a Baird-Parker (BP) culture medium, and the obtained product is placed in a constant-temperature constant-humidity incubator at 37 ℃ for 24 hours.
Single colonies on the medium were picked into tryptone broth (TSB) and cultured for 6h at 37 ℃ on a shaker at 180 r/min.
Sucking 1mL of the above bacterial liquid into a 1.5mL centrifuge tube, centrifuging for 3min at 6000r/min, removing supernatant, adding 0.85% physiological saline, blowing to wash bacteria, mixing, centrifuging (6000r/min, 3min), and repeating for 3 times.
1mL of 0.85% physiological saline is added to resuspend the thalli, the OD value of the bacterial liquid is adjusted to 0.1, and the bacterial liquid is diluted 1000 times by using a TSB culture medium for later use.
Dimethylsulfoxide (DMSO) was used as a solvent to prepare 100mg/mL eugenol mother liquor, which was then diluted to 90/80/70/60/50/40/30/20/10 mg/mL.
To ensure that DMSO in the culture system does not exceed 1%, 297 μ L of the above bacterial solution and 3 μ L of the above eugenol solution with each concentration are added into each hole of the growth curve plate, the periphery of the plate is sealed by 0.85% physiological saline, and the growth curve of Staphylococcus aureus under the action of eugenol is measured by using a growth curve instrument (37 ℃, 24h, and the OD value is measured every 30 min). As shown in FIG. 1, the minimum inhibitory concentrations of eugenol against MRSA standard strain ATCC 43300 and food-derived strain SJTUF21656 and against MSSA standard strain ATCC 29213 and food-derived strain SJTUF 21660 were 1000. mu.g/mL, 800. mu.g/mL, 1000. mu.g/mL and 900. mu.g/mL, respectively.
Example 2: eugenol was tested for its inhibitory effect on the synthesis of Staphylococcus aureus flavins.
Single colonies on BP medium were picked to PA bottles supplemented with 10mL TSB and cultured in a shaker at 37 ℃ and 180r/min for 4 h.
Preparing 50mg/mL eugenol mother liquor by DMSO, respectively diluting to 10/20/30/40mg/mL eugenol mother liquor, respectively sucking 300 mu L eugenol solution with each concentration into 30mL TSB, uniformly mixing, inoculating 300 mu L activated bacterium liquid, and culturing in a shaking table at 37 ℃ and 180r/min for 24 h.
Transferring the bacteria solution after 24h of co-culture into a 50mL centrifuge tube, centrifuging (8000r/min, 5min), removing the supernatant, adding 0.85% physiological saline to wash the bacteria, mixing uniformly, centrifuging (8000r/min, 5min), and repeating for 3 times.
Adding 5mL of methanol into the bacterial sediment, blowing, uniformly mixing, putting into a constant-temperature water bath kettle, and keeping away from light at 55 ℃ for 3h to complete the extraction of the staphylococcal flavin, wherein carvacrol (the final concentration is 80 mug/mL) is used as a positive control of the experiment.
1mL of the supernatant was aspirated into a 1.5mL centrifuge tube, centrifuged (12000r/min, 3min), and 200. mu.L of each supernatant was transferred to a 96-well plate and tested for OD462 nm. As shown in FIG. 2, the minimum inhibitory staphylococcal flavin concentration (MSIC) of 4 strains of S.aureus by eugenol was 300. mu.g/mL.
To further demonstrate the effect of eugenol on staphylococcal flavin synthesis, raman spectra of flavins produced by staphylococcus aureus treated with 1/2MSIC, 2MSIC eugenol were measured using a dispersive confocal raman spectrometer and the CrtN knockout and CrtN gene complementation strains of s. The extraction of staphylococcal flavins was performed as in examples 1 and 2, i.e. methanol extraction. The experimental results are shown in fig. 3:
the staphylococcus flavin is 1008cm-1(methyl vibration), 1161cm-1(C-C stretch) and 1525cm-1There are 3 characteristic raman peaks near (C ═ C stretch). 1161cm with decrease of staphylococcal flavin synthesis-1And 1525cm-1The intensity of the raman peak gradually decreases. This is associated with the large content of C-C and C ═ C in the staphyloxanthin structure.
CrtN is a key enzyme on a staphylococcus flavin synthesis pathway, and staphylococcus aureus with a CrtN gene deletion cannot normally synthesize staphylococcus flavin. Therefore, the Raman spectrogram results of flavin extracted from the culture of the CrtN gene-deleted strain and the CrtN gene-complemented strain confirmed exactly 1161cm-1(C-C stretch) and 1525cm-1The intensity of the Raman peak at (C ═ C stretch) is positively correlated with the amount of staphylococcal flavin synthesized.
In a word, according to the experimental results, the invention provides a new idea for preventing and controlling staphylococcus aureus and has wide application potential in the fields of food, medicine and human health.
The foregoing detailed description of the preferred embodiments of the invention has been presented. It should be understood that numerous modifications and variations could be devised by those skilled in the art in light of the present teachings without departing from the inventive concepts. Therefore, the technical solutions available to those skilled in the art through logic analysis, reasoning and limited experiments based on the prior art according to the concept of the present invention should be within the scope of protection defined by the claims.
Claims (10)
1. A method of inhibiting staphylococcal flavin synthesis comprising the steps of:
step 1, dipping the frozen starting strain for amplification culture, resuspending the strain with physiological saline, adjusting the OD value of the bacterial liquid to 0.1, and then diluting the bacterial liquid with a TSB culture medium;
step 2, preparing a eugenol solution;
step 3, mixing the eugenol solution into the bacterial liquid obtained in the step 1 for co-culture;
and 4, detecting the OD value of the bacteria liquid after co-culture.
2. The method for inhibiting staphylococcal flavin synthesis according to claim 1, wherein in step 1, the bacterial liquid is diluted 1000-fold with TSB culture medium.
3. The method for inhibiting staphylococcal flavin synthesis according to claim 1, wherein in step 1, the normal saline is 1mL of 0.85% normal saline.
4. The method for inhibiting staphylococcal flavin synthesis according to claim 1, wherein step 2 comprises using dimethyl sulfoxide as solvent to prepare 100mg/mL eugenol mother liquor, and diluting to different concentrations.
5. The method for inhibiting staphylococcal flavin synthesis according to claim 1, wherein the co-cultivation time in step 3 is 24 h.
6. The eugenol antibacterial agent prepared by the method for inhibiting the synthesis of the staphylococcal flavin according to the claim 1 or 4, characterized by comprising dimethyl sulfoxide and eugenol, wherein the dimethyl sulfoxide is a solvent.
7. The eugenol antibacterial agent according to claim 6, wherein the eugenol minimum inhibitory concentration MIC is 800-1000 μ g/mL.
8. The eugenol antimicrobial agent according to claim 6, wherein the eugenol minimal inhibitory staphylococcal flavin concentration MSIC is 300 μ g/mL.
9. Use of the eugenol antibacterial agent according to any one of claims 6 to 8 for inhibiting the synthesis of staphylococcus aureus flavins.
10. The use of the eugenol antibacterial agent according to claim 9 for inhibiting the synthesis of staphylococcal flavins, wherein the staphylococcus aureus is methicillin sensitive, methicillin resistant staphylococcus aureus standard strains and food-derived strains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111442761.9A CN114164150A (en) | 2021-11-30 | 2021-11-30 | Method for inhibiting synthesis of staphylococcal flavin and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111442761.9A CN114164150A (en) | 2021-11-30 | 2021-11-30 | Method for inhibiting synthesis of staphylococcal flavin and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114164150A true CN114164150A (en) | 2022-03-11 |
Family
ID=80481895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111442761.9A Pending CN114164150A (en) | 2021-11-30 | 2021-11-30 | Method for inhibiting synthesis of staphylococcal flavin and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114164150A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334755A (en) * | 2017-08-08 | 2017-11-10 | 佛山科学技术学院 | Eugenol/caryophyllus oil is suppressing the application of oral conditions pathogenic bacteria |
| WO2020094767A1 (en) * | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| US20200306295A1 (en) * | 2017-09-22 | 2020-10-01 | Purdue Research Foundation | METHOD AND DEVICE FOR ANNIHILATION OF Staphylococcus aureus |
-
2021
- 2021-11-30 CN CN202111442761.9A patent/CN114164150A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334755A (en) * | 2017-08-08 | 2017-11-10 | 佛山科学技术学院 | Eugenol/caryophyllus oil is suppressing the application of oral conditions pathogenic bacteria |
| US20200306295A1 (en) * | 2017-09-22 | 2020-10-01 | Purdue Research Foundation | METHOD AND DEVICE FOR ANNIHILATION OF Staphylococcus aureus |
| WO2020094767A1 (en) * | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
Non-Patent Citations (3)
| Title |
|---|
| 李海贤;马艳玲;曾荣;: "丁香酚对金黄色葡萄球菌MDH和SDH酶活力的影响", 食品科技, no. 03, 20 March 2018 (2018-03-20) * |
| 梅妹 等: "丁香酚对金黄色葡萄球菌全基因组转录水平的影响研究", 化学与生物工程, vol. 25, no. 6, 31 December 2008 (2008-12-31), pages 1 - 1 * |
| 陶站华;柯珂;师德强;竺利波;: "利用光镊拉曼光谱研究环境因素对葡萄球菌黄素生物合成的影响", 激光与光电子学进展, no. 12, 31 December 2017 (2017-12-31) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sangkanu et al. | Evaluation of antibacterial potential of mangrove sediment-derived actinomycetes | |
| Elexson et al. | Effect of detergents as antibacterial agents on biofilm of antibiotics-resistant Vibrio parahaemolyticus isolates | |
| Hassanshahian et al. | Antimicrobial activity of Trachyspermum ammi essential oil against human bacterial | |
| Ismail-Ben Ali et al. | Jania rubens-associated bacteria: molecular identification and antimicrobial activity | |
| AU2017238644B2 (en) | Methods for treating and preventing C. difficile infection | |
| Zeedan et al. | Antimicrobial, antiviral activity and GC-MS analysis of essential oil extracted from Achillea fragrantissima plant growing in Sinai Peninsula | |
| Techaoei et al. | Chemical evaluation and antibacterial activity of novel bioactive compounds from endophytic fungi in Nelumbo nucifera | |
| Liu et al. | Carvacrol oil inhibits biofilm formation and exopolysaccharide production of Enterobacter cloacae | |
| Marathe et al. | In vitro antibacterial activity of Tabernaemontana alternifolia (Roxb) stem bark aqueous extracts against clinical isolates of methicillin resistant Staphylococcus aureus | |
| Agrawal | Antimicrobial Activity of Nostoc calcicola (Cyanobacteria) isolated from central India against human pathogens | |
| Darabpour et al. | Isolation of a potent antibiotic producer bacterium, especially against MRSA, from northern region of the Persian Gulf | |
| Kumar et al. | In vitro antibacterial screening of six proline-based cyclic dipeptides in combination with β-lactam antibiotics against medically important bacteria | |
| WO2016027279A1 (en) | Novel bacterium of bacillus genus and uses thereof | |
| Adinortey et al. | Isolation of Helicobacter pylori from gastric biopsy of dyspeptic patients in Ghana and in vitro preliminary assessment of the effect of Dissotis rotundifolia extract on its growth | |
| Oyewole et al. | In vitro study of potential probiotic lactic acid bacteria isolated from the gut of chickens in Abeokuta, Nigeria. | |
| Srilekha et al. | Antibacterial and anti-inflammatory activities of marine Brevibacterium sp. | |
| Paopradit et al. | Vibrio alginolyticus influences quorum sensing-controlled phenotypes of acute hepatopancreatic necrosis disease-causing Vibrio parahaemolyticus | |
| Syed Yaacob et al. | Morphological alterations in gram-positive and gram-negative bacteria exposed to minimal inhibitory and bactericidal concentration of raw Malaysian stingless bee honey | |
| Lv et al. | Lactobacillus plantarum CY 1-1: A novel quorum quenching bacteria and anti-biofilm agent against Aeromonas sobria | |
| Chen et al. | Phylogenetic analysis and screening of antimicrobial and antiproliferative activities of culturable bacteria associated with the ascidian Styela clava from the Yellow Sea, China | |
| Krishnamoorthy et al. | Pharmacological activities of coral reef associated actinomycetes, Saccharopolyspora sp. IMA1 | |
| Penduka et al. | Evaluation of the anti-Listeria potentials of some plant-derived triterpenes | |
| Naisi et al. | Antimicrobial and anti-biofilm effects of carotenoid pigment extracted from Rhodotorula glutinis strain on food-borne bacteria | |
| Purwestri et al. | Metabolic profiling of endophytic bacteria from Purwoceng (Pimpinella pruatjan Molkend) root and antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa | |
| CN114164150A (en) | Method for inhibiting synthesis of staphylococcal flavin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |